论文部分内容阅读
应用免疫组织化学方法检测44例肾细胞癌组织中的多药耐药基因产物P糖蛋白（P－GP）的表达。结果63．6％（28／44例）的肾细胞癌有P－GP表达。根据组织病理学分型，发现不同类型的肾细胞癌P－GP表达有所不同，颗粒细胞癌P－GP表达率为90．9％（10／11例），混合型癌（颗粒细胞癌和透明细胞癌）为75．0％（6／8例），乳头状腺癌为50．0％（1／2例），透明细胞癌为47．8％（11／23例）。提示肾细胞癌化疗药物治疗效果差的原因与肿瘤本身容易产生耐药性有关。
Immunohistochemistry was used to detect the expression of P-glycoprotein (P-GP) in 44 renal cell carcinoma tissues. Results 63.6% (28/44 cases) of renal cell carcinoma had P-GP expression. According to the histopathological classification, the expression of P-GP in different types of renal cell carcinoma was found to be different. The positive rate of P-GP in granulosa cell carcinoma was 90.9% (10/11 cases), mixed type carcinoma (6/8), 50.0% (1/2) of papillary adenocarcinomas, and 47.8% (11/23) of clear cell carcinomas. Prompted that the treatment of renal cell carcinoma chemotherapy drugs poor causes of cancer itself is prone to drug resistance.